1. Liu, Xuejiao, Zhao, Simin, Wang, Keke, Li, Xiang, Dong, Zigang. 2023. Spatial transcriptomics analysis of esophageal squamous precancerous lesions and their progression to esophageal cancer. In Nature communications, 14, 4779. doi:10.1038/s41467-023-40343-5. https://pubmed.ncbi.nlm.nih.gov/37553345/
2. Li, Yang, Wang, Xinyu, Xu, Tianye, Jiang, Chuanlu, Meng, Xiangqi. 2024. Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. In Cancer letters, 598, 217107. doi:10.1016/j.canlet.2024.217107. https://pubmed.ncbi.nlm.nih.gov/38992489/
3. Wang, Lidong, Tan, Hao, Huang, Yonglian, Zhao, Huai, Liu, Zhen. 2022. TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT axis. In Endocrine-related cancer, 30, . doi:10.1530/ERC-21-0352. https://pubmed.ncbi.nlm.nih.gov/36222755/
4. Zhuo, Huiqin, Hou, Jingjing, Hong, Zhijun, Xie, Wen, Hong, Xuehui. 2024. TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer. In Cell death & disease, 15, 608. doi:10.1038/s41419-024-07000-1. https://pubmed.ncbi.nlm.nih.gov/39168971/
5. Han, Ming-Zhi, Xu, Ran, Xu, Yang-Yang, Li, Xin-Gang, Wang, Jian. 2017. TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas. In Journal of experimental & clinical cancer research : CR, 36, 155. doi:10.1186/s13046-017-0619-9. https://pubmed.ncbi.nlm.nih.gov/29110682/
6. Zhang, Xiaoyi, Han, Jin, Fan, Di, Huang, Hailan, Gu, Yanting. 2022. Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. In Cancer gene therapy, 30, 172-181. doi:10.1038/s41417-022-00534-6. https://pubmed.ncbi.nlm.nih.gov/36131066/
智鼠故事 
